
Dimitrios P Kontoyiannis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6248309/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	5.8	1,861
2	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
3	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases, 2010, 50, 1101-1111.	5.8	1,281
4	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplantâ€Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases, 2010, 50, 1091-1100.	5.8	1,194
5	Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases, 2012, 54, S23-S34.	5.8	1,061
6	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	13.7	695
7	Zygomycosis in a Tertiaryâ€Care Cancer Center in the Era of <i>Aspergillusâ€</i> Active Antifungal Therapy: A Caseâ€Control Observational Study of 27 Recent Cases. Journal of Infectious Diseases, 2005, 191, 1350-1360.	4.0	659
8	Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. Clinical Infectious Diseases, 2008, 47, 503-509.	5.8	639
9	Glucocorticoids and invasive fungal infections. Lancet, The, 2003, 362, 1828-1838.	13.7	556
10	Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases. Clinical Infectious Diseases, 2006, 42, e61-e65.	5.8	553
11	Pathogenesis of Mucormycosis. Clinical Infectious Diseases, 2012, 54, S16-S22.	5.8	541
12	Zygomycosis in the 1990s in a Tertiary-Care Cancer Center. Clinical Infectious Diseases, 2000, 30, 851-856.	5.8	484
13	Combination Antifungal Therapy for Invasive Aspergillosis. Annals of Internal Medicine, 2015, 162, 81-89.	3.9	376
14	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clinical Infectious Diseases, 2015, 60, 892-899.	5.8	369
15	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	5.8	368
16	Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica, 2006, 91, 986-9.	3.5	357
17	Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases. Clinical Infectious Diseases, 2004, 39, 192-198.	5.8	276
18	Molecular Identification of <i>Aspergillus</i> Species Collected for the Transplant-Associated Infection Surveillance Network. Journal of Clinical Microbiology, 2009, 47, 3138-3141.	3.9	266

#	Article	IF	CITATIONS
19	The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. Journal of Antimicrobial Chemotherapy, 2012, 67, 715-722.	3.0	265
20	Invasive Non- <i>Aspergillus</i> Mold Infections in Transplant Recipients, United States, 2001–2006. Emerging Infectious Diseases, 2011, 17, 1855-1864.	4.3	250
21	On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds. MBio, 2019, 10, .	4.1	231
22	Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clinical Infectious Diseases, 2018, 66, 140-148.	5.8	210
23	Diagnosis of Invasive Septate Mold Infections. American Journal of Clinical Pathology, 2003, 119, 854-858.	0.7	208
24	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20â€year autopsy study. Mycoses, 2013, 56, 638-645.	4.0	198
25	Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. Cell Host and Microbe, 2016, 19, 79-90.	11.0	183
26	Caspofunginâ€Mediated βâ€Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity against <i>Aspergillus</i> and Nonâ€ <i>Aspergillus</i> Hyphae. Journal of Infectious Diseases, 2008, 198, 186-192.	4.0	174
27	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proceedings of the United States of America, 2014, 111, 10660-10665.	7.1	171
28	Mucormycoses. Infectious Disease Clinics of North America, 2016, 30, 143-163.	5.1	162
29	Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell, 2018, 5, 4-31.	3.2	158
30	Mold Infections of the Central Nervous System. New England Journal of Medicine, 2014, 371, 150-160.	27.0	157
31	Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. Journal of Infection, 2010, 60, 331-337.	3.3	145
32	Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections. Journal of Infectious Diseases, 1995, 172, 599-602.	4.0	139
33	Combination Therapy for Mucormycosis: Why, What, and How?. Clinical Infectious Diseases, 2012, 54, S73-S78.	5.8	139
34	Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 2518-2523.	3.2	137
35	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. Journal of Infectious Diseases, 2017, 216, S474-S483.	4.0	135
36	Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses, 2019, 62, 716-729.	4.0	129

#	Article	IF	CITATIONS
37	Drug-ResistantCandida glabrataInfection in Cancer Patients. Emerging Infectious Diseases, 2014, 20, 1833-40.	4.3	127
38	Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. Journal of Infectious Diseases, 2011, 204, 626-635.	4.0	124
39	Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. Journal of Infection, 2012, 64, 68-75.	3.3	124
40	<i>Drosophila melanogaster</i> as a model host to dissect the immunopathogenesis of zygomycosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9367-9372.	7.1	123
41	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196.	4.1	121
42	Aspergillus terreus. Cancer, 2004, 101, 1594-1600.	4.1	120
43	Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis. Journal of Infectious Diseases, 2009, 199, 1399-1406.	4.0	117
44	Generation of IL-23 Producing Dendritic Cells (DCs) by Airborne Fungi Regulates Fungal Pathogenicity via the Induction of TH-17 Responses. PLoS ONE, 2010, 5, e12955.	2.5	105
45	Impact of high-dose granulocyte transfusions in patients with cancer with candidemia. Cancer, 2004, 101, 2859-2865.	4.1	102
46	Frequency and Species Distribution of Gliotoxin-Producing Aspergillus Isolates Recovered from Patients at a Tertiary-Care Cancer Center. Journal of Clinical Microbiology, 2005, 43, 6120-6122.	3.9	99
47	Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood, 2009, 114, 5393-5399.	1.4	99
48	Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infectious Diseases, 2016, 16, 730.	2.9	98
49	Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurology, The, 2018, 17, 362-372.	10.2	93
50	Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrobial Agents and Chemotherapy, 2014, 58, 6993-6995.	3.2	90
51	Epidemiology and treatment of mucormycosis. Future Microbiology, 2013, 8, 1163-1175.	2.0	89
52	Uncommon <i>Candida</i> Species Fungemia among Cancer Patients, Houston, Texas, USA. Emerging Infectious Diseases, 2015, 21, 1942-50.	4.3	87
53	Tollâ€DeficientDrosophilaFlies as a Fast, Highâ€Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis andAspergillusVirulence. Journal of Infectious Diseases, 2005, 191, 1188-1195.	4.0	84
54	Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. Journal of Clinical Investigation, 2016, 126, 2280-2294.	8.2	84

#	Article	IF	CITATIONS
55	Clinical Issues Regarding Relapsing Aspergillosis and the Efficacy of Secondary Antifungal Prophylaxis in Patients with Hematological Malignancies. Clinical Infectious Diseases, 2006, 42, 1584-1591.	5.8	82
56	Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clinical Infectious Diseases, 2018, 67, 1621-1630.	5.8	82
57	Diagnosis of Invasive Septate Mold Infections: A Correlation of Microbiological Culture and Histologic or Cytologic Examination. American Journal of Clinical Pathology, 2003, 119, 854-858.	0.7	82
58	Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Medicine, 2017, 9, 21.	8.2	80
59	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Medical Mycology, 2015, 53, 440-446.	0.7	79
60	Increased frequency of non-fumigatus Aspergillus species in amphotericin B– or triazole–pre-exposed cancer patients with positive cultures for aspergilli. Diagnostic Microbiology and Infectious Disease, 2005, 52, 15-20.	1.8	78
61	Toward more effective antifungal therapy: the prospects of combination therapy. British Journal of Haematology, 2004, 126, 165-175.	2.5	75
62	Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clinical Infectious Diseases, 2018, 67, 1610-1613.	5.8	73
63	Recombinant interferon Î ³ 1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer, 2006, 106, 2664-2671.	4.1	71
64	Caspofungin as Primary Antifungal Prophylaxis in Stem Cell Transplant Recipients. Pharmacotherapy, 2007, 27, 1644-1650.	2.6	69
65	Invasive Mycoses: Strategies for Effective Management. American Journal of Medicine, 2012, 125, S25-S38.	1.5	68
66	Therapeutic Challenges of Non- <i>Aspergillus</i> Invasive Mold Infections in Immunosuppressed Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	68
67	Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-Infective Therapy, 2016, 14, 765-776.	4.4	66
68	Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	66
69	The Candida auris Alert: Facts and Perspectives. Journal of Infectious Diseases, 2018, 217, 516-520.	4.0	66
70	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	3.5	66
71	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in <i>Aspergillus fumigatus</i> . PeerJ, 2013, 1, e4.	2.0	63
72	Environmental Candida auris and the Global Warming Emergence Hypothesis. MBio, 2021, 12, .	4.1	62

DIMITRIOS P KONTOYIANNIS

#	Article	IF	CITATIONS
73	Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clinical Infectious Diseases, 2020, 71, 63-71.	5.8	61
74	The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Medical Mycology, 2008, 46, 23-29.	0.7	60
75	Recent advances in the molecular diagnosis of mucormycosis. Expert Review of Molecular Diagnostics, 2018, 18, 845-854.	3.1	60
76	Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center. Cancer, 2011, 117, 3424-3433.	4.1	58
77	Overexpression of Erg11p by the Regulatable <i>GAL1</i> Promoter Confers Fluconazole Resistance in <i>Saccharomyces cerevisiae</i> . Antimicrobial Agents and Chemotherapy, 1999, 43, 2798-2800.	3.2	56
78	Antifungal Activity of Colistin against <i>Mucorales</i> Species <i>In Vitro</i> and in a Murine Model of <i>Rhizopus oryzae</i> Pulmonary Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 484-490.	3.2	56
79	Tacrolimus Enhances the Potency of Posaconazole Against Rhizopus oryzae In Vitro and in an Experimental Model of Mucormycosis. Journal of Infectious Diseases, 2013, 207, 834-841.	4.0	55
80	Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. Frontiers in Immunology, 2017, 8, 1939.	4.8	52
81	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015. Clinical Infectious Diseases, 2017, 65, 216-225.	5.8	50
82	Molecular Typing of Aspergillus terreus Isolates Collected in Houston, Texas, and Innsbruck, Austria: Evidence of Great Genetic Diversity. Journal of Clinical Microbiology, 2007, 45, 2686-2690.	3.9	49
83	Increased Culture Recovery of Zygomycetes Under Physiologic Temperature Conditions. American Journal of Clinical Pathology, 2007, 127, 208-212.	0.7	48
84	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical Infectious Diseases, 2021, 72, 1755-1763.	5.8	48
85	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS ONE, 2015, 10, e0139851.	2.5	47
86	Invasive fungal disease and cytomegalovirus infection: is there an association?. Current Opinion in Infectious Diseases, 2018, 31, 481-489.	3.1	47
87	Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. Clinical Infectious Diseases, 2022, 75, 534-544.	5.8	47
88	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood, 2015, 126, 2790-2797.	1.4	46
89	Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. PLoS ONE, 2016, 11, e0150155.	2.5	46
90	Aspergillus Hyphae in Infected Tissue: Evidence of Physiologic Adaptation and Effect on Culture Recovery. Journal of Clinical Microbiology, 2005, 43, 382-386.	3.9	45

#	Article	IF	CITATIONS
91	Antifungal Resistance: An Emerging Reality and A Global Challenge. Journal of Infectious Diseases, 2017, 216, S431-S435.	4.0	45
92	Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6767-6772.	3.2	42
93	Resistance to echinocandins comes at a cost. Virulence, 2012, 3, 95-97.	4.4	40
94	Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiology, 2015, 10, 693-708.	2.0	40
95	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 757-763.	3.0	40
96	Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. Journal of Fungi (Basel, Switzerland), 2019, 5, 57.	3.5	37
97	Checkpoint Inhibition and Infectious Diseases: A Good Thing?. Trends in Molecular Medicine, 2019, 25, 1080-1093.	6.7	37
98	AspergillusSusceptibility Testing in Patients with Cancer and Invasive Aspergillosis: Difficulties in Establishing Correlation Between In Vitro Susceptibility Data and the Outcome of Initial Amphotericin B Therapy. Pharmacotherapy, 2005, 25, 1174-1180.	2.6	36
99	Resistance to Antifungal Drugs. Infectious Disease Clinics of North America, 2021, 35, 279-311.	5.1	36
100	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 17.	3.5	36
101	<i>Drosophila melanogaster</i> as a model to study virulence and azole treatment of the emerging pathogen <i>Candida auris</i> . Journal of Antimicrobial Chemotherapy, 2019, 74, 1904-1910.	3.0	35
102	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer, 2021, 127, 2489-2499.	4.1	34
103	The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer. Cancer, 2004, 100, 165-172.	4.1	32
104	Interstrain variability in the virulence of <i>Aspergillus fumigatus</i> and <i>Aspergillus terreus</i> in a <i>Toll</i> deficient <i>Drosophila</i> fly model of invasive aspergillosis. Medical Mycology, 2010, 48, 310-317.	0.7	32
105	Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of <i>Candida</i> and <i>Aspergillus</i> species. Virulence, 2011, 2, 280-295.	4.4	31
106	Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses, 2019, 62, 81-86.	4.0	31
107	Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of <i>Rhizopus oryzae </i> . Journal of Infectious Diseases, 2016, 214, 114-121.	4.0	30
108	Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000–2016): Uncommon, with improved survival but still deadly often. Journal of Infection, 2017, 75, 572-580.	3.3	30

#	Article	IF	CITATIONS
109	Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?. Journal of Infection, 2012, 65, 262-268.	3.3	28
110	Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America, 2011, 25, 193-213.	2.2	27
111	Recent Advances in the Use of <i>Drosophila melanogaster</i> as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. International Journal of Microbiology, 2012, 2012, 1-10.	2.3	26
112	Pentamidine Is Active In Vitro against Fusarium Species. Antimicrobial Agents and Chemotherapy, 2003, 47, 3252-3259.	3.2	25
113	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infectious Diseases, 2022, 9, .	0.9	25
114	Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. Open Forum Infectious Diseases, 2019, 6, ofz247.	0.9	24
115	Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey — Houston, Texas, 2017. Morbidity and Mortality Weekly Report, 2019, 68, 469-473.	15.1	24
116	The impact of azole resistance on aspergillosis guidelines. Annals of the New York Academy of Sciences, 2012, 1272, 15-22.	3.8	23
117	A Long-Term Survivor of Disseminated Aspergillus and Mucorales Infection: An Instructive Case. Mycopathologia, 2014, 178, 465-470.	3.1	23
118	Aspergillus terreus Species Complex. Clinical Microbiology Reviews, 2021, 34, e0031120.	13.6	23
119	Proangiogenic Growth Factors Potentiate In Situ Angiogenesis and Enhance Antifungal Drug Activity in Murine Invasive Aspergillosis. Journal of Infectious Diseases, 2013, 207, 1066-1074.	4.0	22
120	The â€~cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy, 2015, 16, 1543-1558.	1.8	22
121	Fulminant <i>Cryptococcus neoformans</i> infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib <i>:</i> Case report and review of fungal pericarditis. Mycoses, 2018, 61, 245-255.	4.0	22
122	Echinocandinâ€Based Initial Therapy in Fungemic Patients with Cancer: A Focus on Recent Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 49, 638-639.	5.8	21
123	Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. ACS Biomaterials Science and Engineering, 2017, 3, 1207-1220.	5.2	21
124	Breath-Based Diagnosis of Invasive Mucormycosis (IM). Open Forum Infectious Diseases, 2017, 4, S53-S54.	0.9	20
125	Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. MBio, 2019, 10, .	4.1	20
126	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. Journal of Infection, 2019, 78, 484-490.	3.3	20

DIMITRIOS P KONTOYIANNIS

#	Article	IF	CITATIONS
127	Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model. Journal of Infectious Diseases, 2020, 222, 989-994.	4.0	19
128	Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Frontiers in Immunology, 2022, 13, 838344.	4.8	19
129	Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. Medical Mycology, 2012, 50, 543-548.	0.7	18
130	Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. MSphere, 2020, 5, .	2.9	18
131	Diagnosis and Treatment of Invasive Fungal Infections in the Cancer Patient: Recent Progress and Ongoing Questions. Clinical Infectious Diseases, 2014, 59, S356-S359.	5.8	17
132	Rhodotorula infection in haematological patient: Risk factors and outcome. Mycoses, 2019, 62, 223-229.	4.0	17
133	Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. Journal of Fungi (Basel, Switzerland), 2021, 7, 217.	3.5	17
134	Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Medical Mycology, 2010, 48, 1-9.	0.7	17
135	Effect of fluconazole on agar invasion by Candida albicans. Journal of Medical Microbiology, 2001, 50, 78-82.	1.8	17
136	Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget, 2018, 9, 31244-31252.	1.8	17
137	Disseminated cryptococcosis and antiâ€granulocyteâ€macrophage colonyâ€stimulating factor autoantibodies: An underappreciated association. Mycoses, 2021, 64, 576-582.	4.0	16
138	Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model. MSphere, 2022, 7, e0081721.	2.9	16
139	Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clinical Infectious Diseases, 2022, 75, 1503-1510.	5.8	16
140	How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. Clinical Infectious Diseases, 2020, 71, 685-692.	5.8	15
141	Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis?. MBio, 2022, 13, e0047322.	4.1	15
142	Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses, 2018, 61, 861-867.	4.0	14
143	Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy. Clinical Infectious Diseases, 2019, 69, 1624-1627.	5.8	14
144	Nonâ€ <i>Aspergillus</i> invasive mould infections in patients treated with ibrutinib. Mycoses, 2020, 63, 787-793.	4.0	14

#	Article	IF	CITATIONS
145	Progressive Disseminated Aspergillosis in a Bone Marrow Transplant Recipient: Response with a High-Dose Lipid Formulation of Amphotericin B. Clinical Infectious Diseases, 2001, 32, e94-e96.	5.8	13
146	Rational approach to pulmonary infiltrates inÂleukemia and transplantation. Best Practice and Research in Clinical Haematology, 2013, 26, 301-306.	1.7	13
147	Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. Journal of Antimicrobial Chemotherapy, 2015, 70, 3100-3106.	3.0	13
148	Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Pre– and Post–Hurricane Harvey. Open Forum Infectious Diseases, 2019, 6, ofz138.	0.9	13
149	Preexposure to Isavuconazole Increases the Virulence of <i>Mucorales</i> but Not <i>Aspergillus fumigatus</i> in a <i>Drosophila melanogaster</i> Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
150	How to prophylax against invasive fungal infections in adult <scp>ALL</scp> ? An unmet need. Mycoses, 2018, 61, 646-649.	4.0	12
151	Serum Levels of Crushed Posaconazole Delayed-Release Tablets. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	12
152	Anidulafungin versus Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible Candida parapsilosis Isolates with Different Degrees of Caspofungin Susceptibility. Antimicrobial Agents and Chemotherapy, 2014, 58, 229-236.	3.2	11
153	Acute acalculous cholecystitis due to <i>Fusarium</i> species and review of the literature on fungal cholecystitis. Mycoses, 2019, 62, 847-853.	4.0	11
154	Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. Clinical Infectious Diseases, 2020, 71, 1802-1803.	5.8	11
155	Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 294-297.	3.2	10
156	Associations of inflammation with symptom burden in patients with acute myeloid leukemia. Psychoneuroendocrinology, 2018, 89, 203-208.	2.7	10
157	Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
158	Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds. MBio, 2020, 11, .	4.1	10
159	Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. Antimicrobial Agents and Chemotherapy, 2015, 59, 7830-7832.	3.2	9
160	EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Cell Reports, 2021, 34, 108896.	6.4	9
161	<scp>PET</scp> â€positive lymphadenopathy in <scp>CLL</scp> —Not always <scp>R</scp> ichter transformation. American Journal of Hematology, 2017, 92, 405-406.	4.1	8
162	A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. Journal of Clinical Microbiology, 2019, 57, .	3.9	8

#	Article	IF	CITATIONS
163	Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	8
164	European confederation of medical mycology expert consult—An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	4.0	8
165	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (nonâ€ <i>fumigatus</i>): A multicentre, nonâ€interventional registry study. Mycoses, 2022, 65, 186-198.	4.0	7
166	Live imaging and quantitative analysis of <i>Aspergillus fumigatus</i> growth and morphology during inter-microbial interaction with <i>Pseudomonas aeruginosa</i> . Virulence, 2020, 11, 1329-1336.	4.4	6
167	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood, 2020, 136, 2741-2753.	1.4	6
168	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transplant Infectious Disease, 2001, 3, 29-33.	1.7	5
169	Is it Safe to Proceed with Stem Cell Transplant in Cancer Patients Treated for Cryptococcal Infection? A Focus on Recent IDSA Cryptococcal Guidelines. Clinical Infectious Diseases, 2010, 50, 1687-1689.	5.8	5
170	A murine model of cutaneous aspergillosis for evaluation of biomaterialsâ€based local delivery therapies. Journal of Biomedical Materials Research - Part A, 2019, 107, 1867-1874.	4.0	5
171	Cat Scratch Disease as a Mimicker of Malignancy. Open Forum Infectious Diseases, 2021, 8, ofab500.	0.9	5
172	Invasive mould infections in patients from floodwater- damaged areas after hurricane Harvey – a closer look at an immunocompromised cancer patient population. Journal of Infection, 2022, , .	3.3	5
173	1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Open Forum Infectious Diseases, 2014, 1, S37-S37.	0.9	4
174	Infectious complications among patients with AML treated with immune checkpoint inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
175	Taking a Closer Look: Clinical and Histopathological Characteristics of Culture-Positive versus Culture-Negative Pulmonary Mucormycosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 380.	3.5	3
176	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. American Journal of Hematology, 2017, 92, 119-120.	4.1	2
177	Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagnostic Microbiology and Infectious Disease, 2019, 95, 166-170.	1.8	2
178	255. Breakthrough Mucormycosis (BT-MCR) on Antifungals Having Mucorales Activity Portrays Worse Prognosis compared with BT-MCR on Mold-Active Antifungals with no Mucorales Activity. Open Forum Infectious Diseases, 2019, 6, S142-S142.	0.9	2
179	Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Frontiers in Cellular and Infection Microbiology, 2022, 12, 848580.	3.9	2
180	Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris. Methods in Molecular Biology, 2022, , 299-316.	0.9	2

DIMITRIOS P KONTOYIANNIS

#	Article	IF	CITATIONS
181	Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. Medical Mycology, 2019, 57, 639-642.	0.7	1
182	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27–30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology, 2020, 58, 569-578.	0.7	1
183	Effect of high-dose posaconazole on serum levels in adult patients with hematologic malignancy. Antimicrobial Agents and Chemotherapy, 2021, 65, e0123021.	3.2	1
184	Fungal Infections in Cancer Patients. , 2021, , 792-802.		1
185	991. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Mortality, Infection Severity, and Fungal Clearance in an Immunosuppressed Murine Model of Invasive Pulmonary Mucormycosis. Open Forum Infectious Diseases, 2021, 8, S586-S586.	0.9	1
186	1446Fungemia due to Uncommon Candida species in Patients with Cancer: Increasing Incidence, Frequent Resistance and High Mortality rates. Open Forum Infectious Diseases, 2014, 1, S380-S381.	0.9	0
187	359. Baseline Serum <i>Aspergillus</i> Galactomannan Index Among <i>Aspergillus</i> Species in Hematologic Malignancies Patients With Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2018, 5, S141-S141.	0.9	0
188	ls Candida auris here to stay? An interview with Dimitrios Kontoyiannis. Future Microbiology, 2019, 14, 1083-1085.	2.0	0
189	Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. Medical Mycology, 2021, 59, 102-105.	0.7	0
190	Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata. Microbiology Spectrum, 2022, 10, e0183721.	3.0	0